Turnstone Biologics Valuation
| TSBX Stock | 0.52 0.01 1.96% |
Turnstone Biologics is undervalued. Turnstone Biologics Corp has a current Real Value of USD4.62 per share. The regular price of the company is USD0.52. Our model measures the value of Turnstone Biologics Corp from inspecting the company fundamentals such as Shares Owned By Institutions of 65.64 %, return on equity of -1.34, and Shares Outstanding of 23.13 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Turnstone Biologics' valuation include:
Price Book 0.2676 | Enterprise Value -31.9 M | Enterprise Value Ebitda 0.7977 | Price Sales 2.1344 |
Undervalued
Today
Please note that Turnstone Biologics' price fluctuation is unstable at this time. Calculation of the real value of Turnstone Biologics Corp is based on 3 months time horizon. Increasing Turnstone Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Turnstone Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Turnstone Stock. However, Turnstone Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.52 | Real 4.62 | Target 17.0 | Hype 0.51 | Naive 0.56 |
The intrinsic value of Turnstone Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Turnstone Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Turnstone Biologics Corp helps investors to forecast how Turnstone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Turnstone Biologics more accurately as focusing exclusively on Turnstone Biologics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Turnstone Biologics' intrinsic value based on its ongoing forecasts of Turnstone Biologics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Turnstone Biologics' closest peers.
Turnstone Biologics Cash |
|
Turnstone Valuation Trend
Analysing the historical paterns of Turnstone Biologics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Turnstone Biologics Corp over time and is usually enough for investors to make rational market timing decisions.
Turnstone Biologics Total Value Analysis
Turnstone Biologics Corp is at this time forecasted to have valuation of (31.91 M) with market capitalization of 13.39 M, debt of 3.21 M, and cash on hands of . The negative valuation of Turnstone Biologics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Turnstone Biologics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(31.91 M) | 13.39 M | 3.21 M |
Turnstone Biologics Investor Information
About 66.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Turnstone Biologics Corp recorded a loss per share of 3.23. The entity had not issued any dividends in recent years. Based on the key indicators related to Turnstone Biologics' liquidity, profitability, solvency, and operating efficiency, Turnstone Biologics Corp may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Turnstone Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Turnstone Biologics has an asset utilization ratio of 17.11 percent. This suggests that the Company is making USD0.17 for each dollar of assets. An increasing asset utilization means that Turnstone Biologics Corp is more efficient with each dollar of assets it utilizes for everyday operations.Turnstone Biologics Ownership Allocation
Turnstone Biologics Corp shows a total of 23.13 Million outstanding shares. Over half of Turnstone Biologics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Turnstone Biologics Profitability Analysis
The company reported the previous year's revenue of 19.31 M. Net Loss for the year was (55.2 M) with profit before overhead, payroll, taxes, and interest of 71.13 M.About Turnstone Biologics Valuation
Our relative valuation model uses a comparative analysis of Turnstone Biologics. We calculate exposure to Turnstone Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Turnstone Biologics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 16.5 M | 15.7 M | |
| Pretax Profit Margin | (2.87) | (2.73) | |
| Operating Profit Margin | (3.06) | (2.90) | |
| Net Loss | (2.86) | (2.72) | |
| Gross Profit Margin | 0.85 | 1.03 |
Turnstone Biologics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 11.6 M |
Turnstone Biologics Current Valuation Indicators
Valuation refers to the process of determining the present value of Turnstone Biologics Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Turnstone we look at many different elements of the entity such as Turnstone's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Turnstone Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Turnstone Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Turnstone Biologics' worth.Additional Tools for Turnstone Stock Analysis
When running Turnstone Biologics' price analysis, check to measure Turnstone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Turnstone Biologics is operating at the current time. Most of Turnstone Biologics' value examination focuses on studying past and present price action to predict the probability of Turnstone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Turnstone Biologics' price. Additionally, you may evaluate how the addition of Turnstone Biologics to your portfolios can decrease your overall portfolio volatility.